Paul Royalty buys share of Rotarix royalties from CCHMC
Executive Summary
The Paul Royalty Fund has bought a share of the royalties owed to three researchers at the Cincinnati Children's Hospital Medical Center from GlaxoSmithKline for GSK's worldwide sale of Rotarix, an oral vaccine against rotavirus that the researchers originally helped develop.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Royalty Sale
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice